1Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma [ J ]. N Engl J Med, 2007, 356 (2) :125 - 134.
2Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progres- sion and angiogenesis [ J ]. Cancer Res, 2004, 64 ( 19 ) : 7099 -7109.
3Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants [ J]. J Natl Cancer Inst, 2006,98 (5) : 326 - 334.